RxDoctor Payments Data

Micaela Crowley

Optometrist · Westminster, MANPI 1891248084

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $56,248 of the $87,762 with a category attached, or 64.1%. Coopervision Inc. accounts for 60.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $24,118 and has fallen 97.4% since, to $631 in 2025. Among optometrist clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,762in general payments, 2019–2025

Across 175 payments — averaging $501.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$53K
  • Oyster Point Pharma, Inc.$26K
  • Kala Pharmaceuticals, Inc.$5K
  • Novartis$2K
  • Shire North American Group Inc$949
  • Carl Zeiss Meditec USA, Inc.$491
  • plus $608 from 8 others
$7,275in research payments, 2019–2025

Across 1 payment — averaging $7275.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$7K

What the payments were for

  • Consulting fees$10,58812%
  • Speaking & faculty fees$56,24864%
  • Travel & lodging$17,02119%
  • Food & beverage$3,9064%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,762 in reported general payments places this provider in the 95th percentile of 1,084 optometrist providers in Massachusetts.

See all optometrist providers in Massachusetts

Medicare billing

Part B allowed, 2024
$35,370
Medicare patients
178
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast36$53,069
RestasisCyclosporine19$35,414
Restasis MultidoseCyclosporine18$18,974
ErythromycinErythromycin Base11$129

Paid to pharmacies, not to this prescriber.

Other optometrist in Westminster

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →